1. Comparison of MALDI‐TOF mass spectrometry analysis of peripheral blood and bone marrow‐based flow cytometry for tracking measurable residual disease in patients with multiple myeloma. (5th February 2020) Authors: Eveillard, Marion; Rustad, Even; Roshal, Mikhail; Zhang, Yanming; Ciardiello, Amanda; Korde, Neha; Hultcrantz, Malin; Lu, Sydney; Shah, Urvi; Hassoun, Hani; Smith, Eric; Lesokhin, Alexander; Mailankody, Sham; Landgren, Ola; Thoren, Katie Journal: British journal of haematology Issue: Volume 189:Number 5(2020) Page Start: 904 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade. Issue 1 (14th May 2020) Authors: Yang, Rui; Elsaadi, Samah; Misund, Kristine; Abdollahi, Pegah; Vandsemb, Esten Nymoen; Moen, Siv Helen; Kusnierczyk, Anna; Slupphaug, Geir; Standal, Therese; Waage, Anders; Slørdahl, Tobias S; Rø, Torstein Baade; Rustad, Even; Sundan, Anders; Hay, Carl; Cooper, Zachary; Schuller, Alwin G; Woessne... Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity. (March 2021) Authors: Diamond, Benjamin T.; Rustad, Even; Maclachlan, Kylee; Thoren, Katie; Ho, Caleb; Roshal, Mikhail; Ulaner, Gary A.; Landgren, C. Ola Journal: Blood reviews Issue: Volume 46(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗